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Abstract
G-protein coupled receptors (GPCRs) modulate many physiological processes by transducing a 
variety of extracellular cues into intracellular responses. Ligand binding to an extracellular 
orthosteric pocket propagates conformational change to the receptor cytosolic region to promote 
binding and activation of downstream signaling effectors such as G proteins and β-arrestins. It is 
widely appreciated that different agonists can share the same binding pocket but evoke unique 
receptor conformations leading to a wide range of downstream responses (i.e., ‘efficacy’)1. 
Furthermore, mounting biophysical evidence, primarily using the β-adrenergic receptor (β2AR) as 
a model system, supports the existence of multiple active and inactive conformational states2–5. 
However, how agonists with varying efficacy modulate these receptor states to initiate cellular 
responses is not well understood. Here we report stabilization of two distinct β2AR conformations 
using single domain camelid antibodies (nanobodies): a previously described positive allosteric 
nanobody (Nb80) and a newly identified negative allosteric nanobody (Nb60)6,7. We show that 
Nb60 stabilizes a previously unappreciated low affinity receptor state which corresponds to one of 
two inactive receptor conformations as delineated by X-ray crystallography and NMR 
spectroscopy. We find that the agonist isoproterenol has a 15,000-fold higher affinity for the β2AR 
in the presence of Nb80 compared to Nb60, highlighting the full allosteric range of a GPCR. 
Assessing the binding of 17 ligands of varying efficacy to the β2AR in the absence and presence of 
Nb60 or Nb80 reveals large ligand-specific effects that can only be explained using an allosteric 
model which assumes equilibrium amongst at least three receptor states. Agonists generally exert 
efficacy by stabilizing the active Nb80-stabilized receptor state (R80). In contrast, for a number of 
partial agonists, both stabilization of R80 and destabilization of the inactive, Nb60-bound state 
(R60) contribute to their ability to modulate receptor activation. These data demonstrate that 
ligands can initiate a wide range of cellular responses by differentially stabilizing multiple 
receptor states.
The allosteric behavior of GPCRs is responsible for the complex signaling properties 
associated with these important regulators of human physiology. GPCR allostery, defined 
here as a linkage between the extracellular orthosteric ligand pocket and the intracellular G-
protein binding pocket, has long been analyzed by pharmacological methods8–10 (see 
supplemental material for additional information). Conformational changes within a GPCR 
induced by agonist binding can enhance the affinity and binding of intracellular signaling 
transducers, such as G-proteins and β-arrestins. Conversely, transducer coupling further 
enhances agonist affinity, resulting in the formation of the ternary complex of receptor, 
transducer, and ligand (Fig. 1a). The conceptual framework of the ternary complex model 
(TCM) equates the magnitude of these affinity changes with the strength of transducer 
activation in cells11,12, as demonstrated for several GPCR systems13–16. However, the 
structural basis underlying these allosteric relationships and how they relate to ligand 
efficacy is not well understood.
Ligand-dependent GPCR activation has traditionally been conceptualized as a conversion 
between a single inactive and a single active receptor state. However, recent studies utilizing 
various spectroscopic techniques have identified multiple inactive and active receptor states, 
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suggesting that the mechanisms underlying receptor activation may be more complex than 
previously thought2–5. To better understand how ligands with varying efficacies may 
differentially regulate these conformations, we sought to develop reagents to stabilize 
specific inactive and active conformations of the β2AR. We and others have previously 
utilized Nb80, a Gs mimetic nanobody, to stabilize an active conformation of the β2AR6,7. 
Indeed, competition radioligand binding assays using iodinated cyanopindolol ([125I]-CYP) 
and β2AR reconstituted into high-density lipoprotein (HDL) particles (nanodiscs) 
demonstrated that Nb80 increases the affinity of the agonist isoproterenol (ISO) by 75 fold 
(Fig. 1b), which is similar, but not identical, to the 33 fold increase seen in the presence of 
purified heterotrimeric Gs (Fig. 1b). To investigate the pharmacological properties of the 
inactive receptor we identified a nanobody (Nb60) that preferentially bound inverse agonist-
bound β2AR7. Remarkably, though the affinity of the receptor for agonist in the absence of 
Gs or Nb80 was presumed to reflect the pharmacological properties of the inactive state, the 
presence of Nb60 reduced agonist affinity by approximately 70 fold (Fig. 1b). The effects of 
Nb60 and Nb80 on radiotracer affinity were negligible and could not account for the large 
changes in affinity (Extended Data Table 1).
To further quantitate the allosteric effects of Nb60 and Nb80/Gs on agonist binding, we 
measured ISO affinity with radioligand competition binding over a range of nanobody/Gs 
concentrations (Extended Data Figure 1). As the concentration of allosteric modulator 
increases, the effect on ISO affinity becomes saturable, reaching two opposite plateau values 
with Nb60 and Nb80/Gs (Fig. 1c). This is a hallmark pattern of true allosteric interactions, 
with the net log-change in ISO affinity at saturating concentration of nanobody/Gs gauging 
the extent of cooperativity between nanobody and agonist binding (negative for Nb60 or 
positive for Nb80/Gs) (see supplemental information). As predicted by the TCM, this 
coupling energy, termed α, must be constant; i.e. the effect of bound nanobody on agonist 
binding is reciprocal to the effect of bound agonist on nanobody binding. To verify such a 
prediction, we measured the affinity of Nb60 for the β2AR in the absence and presence of 
agonist (ISO) using isothermal titration calorimetry (Fig. 1d, e). As expected the affinity of 
Nb60 for β2AR decreased in the presence of ISO. Consistent with its preference for the 
inactive state, Nb60 dose-dependently increased binding of the radiolabeled inverse 
antagonist [3H]-ICI-118,551 to the β2AR, whereas binding was decreased in the presence of 
Nb80 (Fig. 1f). Taken together, these data show that Nb60 and Nb80 are potent allosteric 
modulators that can be used to stabilize inactive and active β2AR states.
The decrease in ISO affinity observed in the presence of Nb60 reveals a previously 
unappreciated “very low affinity” state (KVL) in competition binding experiments. The 
affinity of agonist for an uncoupled GPCR has traditionally been referred to as the “low 
affinity” (KL) state; however, our results show that KL values reflect binding of an ensemble 
of conformations that exchange rapidly over the course of the binding reaction. This 
phenomenon is likely conserved among GPCRs as a similar KVL state has been observed 
with the A(2A) adenosine receptor using an antibody fragment17. This conformational 
heterogeneity is consistent with recent spectroscopic and computational studies, which have 
shown that the β2AR exists in multiple inactive, intermediate, and active conformations that 
exchange within milliseconds2–5,18. To assess which receptor state Nb60 stabilizes, we 
conducted 19F-fluorine NMR spectroscopy of β2AR labeled with a trifluoroacetanilide probe 
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at the endogenous residue C265 located at the cytoplasmic end of transmembrane 6 (TM6). 
As shown previously, the unliganded β2AR exists in two equally distributed inactive states 
(termed S1 and S2) that exchange on a fast timescale (700 ± 137 µs), and complete 
conversion into the active S4 state requires both agonist and transducer binding (Fig. 2a,b)5. 
Using structural insights from double electron-electron resonance studies, S1 was identified 
as an inactive state with an interaction between TM3 residue R1313.50 (superscripts indicate 
Ballesteros-Weinstein numbering for GPCRs19) and E2686.30 in TM65, commonly termed 
the ionic lock. The ionic lock has previously been shown to be important in maintaining the 
inactive conformation of β2AR, as charge neutralizing mutations at these positions increase 
receptor constitutive activity20. Additionally, the S2 conformation was also identified as an 
inactive state but with a disengaged ionic lock (Fig 2b). The binding of G-protein or other 
positive allosteric modulators such as Nb80 lowers the energy of the active receptor states, 
driving the receptor from S2 towards active conformations5. The 19F-NMR spectra showed 
that the addition of Nb60 to β2AR bound to the inverse agonist carazolol shifted the S1–S2 
equilibrium towards the inactive S2 state (Fig. 2c), providing a mechanism for its negative 
cooperative effects on ISO affinity. Given the broad NMR line shape (Fig. 3c, red line) of the 
β2AR when bound to carazolol and Nb60, we conducted Carr-Purcell-Meiboom-Gill 
(CPMG)21 relaxation dispersion measurements to measure potential conformational 
heterogeneity. Indeed, we found that the β2AR when bound to Nb60 and carazolol 
interconverts (860 +/− 530 s−1) between S1 and S2 but is predominantly found (75–90%) in 
the S2 inactive state (Extended Data Figure 1d).
To further decipher how Nb60 induces a negative cooperative effect on agonist binding, we 
determined a 3.2Å X-ray crystal structure of a ternary complex comprised of β2AR, Nb60, 
and the inverse agonist carazolol (Fig. 2d–f, Extended Data Figure 2, Extended Data Table 
2). The complementary determining region 3 (CDR3) of Nb60 inserts into a similar β2AR 
allosteric pocket as G-protein and Nb80, located between the cytoplasmic ends of TM3, 
TM4 and TM6 (Fig. 2d, e). We found that T102 and Y106 in Nb60 bridge an interaction 
between residues R1313.50 and E2686.30. This interaction does not exist in the absence of 
Nb60 (PDB ID: 2RH1), indicating that Nb60 stabilizes an inactive conformation through 
interactions with the β2AR ionic lock (Fig. 2e). However, this polar network appears 
“disengaged” compared to the fully closed ionic lock in the β1-adrenergic receptor (PDB ID: 
2YCW22) (Fig. 2e), thus supporting the 19F-NMR data showing that Nb60 specifically 
stabilizes the S2 inactive state. The insertion of Nb60 F103 into a hydrophobic pocket in the 
β2AR may also contribute to the affinity and/or negative allosteric properties of Nb60 
(Extended Data Figure 2c). Confirming the importance of T102 and F103 for the β2AR-
Nb60 interaction, alanine mutations at these positions inhibited Nb60 binding to the β2AR 
and the negative cooperative effects on ISO binding (Extended Data Figure 2e,f). Other than 
changes within the ionic lock, the overall structure of β2AR bound to Nb60 is highly similar 
to the previously determined inactive β2AR structure bound to carazolol alone (RMSD 0.3 Å 
for the transmembrane domains and orthosteric binding pocket, Fig. 2f). Taken together, the 
pharmacological, biophysical, and crystallographic studies show that Nb60 exerts its 
negative allosteric effect on agonist binding by stabilizing the S2 inactive β2AR 
conformation.
Staus et al. Page 4
Nature. Author manuscript; available in PMC 2017 January 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our observation that ISO bound to the Nb80-stabilized active β2AR with approximately 
15,000-fold greater affinity than to the Nb60-stabilized inactive β2AR (Fig. 1b and c) 
provides a measurement of the full allosteric power of an agonist to activate a GPCR. The 
large free energy difference (−24 kJ/mol) between these states is likely important for GPCR 
function, allowing agonist-stimulated activity to be significantly higher than that of the basal 
activity. As simulated for a full agonist in Figure 3a, the overall affinity shift from inactive to 
active receptor (black arrow) is comprised of two components, the negative cooperative 
effects of Nb60 (αNb60, blue) and positive effects of Nb80 (αNb80, red). Given the 
complexities and limitations of using NMR and crystallography to gain mechanistic insights 
into ligand activation of a GPCR, we utilized a pharmacological approach to quantify 
αNb60 and αNb80 for 17 β2AR ligands of varying efficacy (Fig. 3b, Extended Data Figure 
3).
We first identified a significant positive correlation (r = 0.8514, p = 0.004) between αNb80 
values (i.e., KL/KH ratios) and the relative intrinsic efficacies (i.e., τ ratios) of various 
ligands obtained from cellular G-protein assays (Extended Data Figure 4a–b). This finding 
provides additional support for the claim that Nb80 exerts allosteric effects that mimic those 
of a G protein. It also confirms our previous reports that ligand efficacy is not a product of 
modified downstream signaling events but is rather achieved at the level of ternary complex 
interactions, reflecting the allosteric interactions between different ligands and 
‘transducers’12. Interestingly, we find no significant correlation between αNb60 and ligand 
efficacy, providing the first evidence that ligands perceive the Nb60 and Nb80 stabilized 
receptor states differently (Extended Data Figure 4c). Next we observed a significant 
negative correlation (r = 0.7417, p = 0.0013) between αNb60 and αNb80 values (Fig. 3c) 
across all ligands, suggesting these nanobodies stabilize functionally opposite 
conformations. However, the relationship between αNb60 and αNb80 was unexpectedly 
complex (Fig. 3b). For example, several full agonists exhibited comparable levels of positive 
(Nb80) and negative (Nb60) cooperativity (i.e., norepinephrine, epinephrine, and 
isoproterenol), while some partial agonists displayed surprisingly discrepant patterns (i.e., 
clenbuterol, salbutamol, and zinterol) (Fig. 3b). Importantly, for a subset of these ligands we 
confirmed that the allosteric effects of Nb80 are consistent with those elicited by the 
physiological transducer heterotrimeric Gs (Extended Data Figure 5a,b), Moreover, the 
surprisingly divergent, ligand-specific effects of Nb60 were also observed with another 
inactive state-stabilizing nanobody, A11 (Extended Data Figure 5c). Together, these data 
indicate that the ligand-specific effects of Nb80 and Nb60 are not nanobody-specific but 
rather reflect how ligands perceive specific receptor conformations.
We next tested two different allosteric models to try to explain how the different 
conformations stabilized by Nb60 and Nb80 can generate the observed cooperativities. First 
we tested whether the dynamics of receptor states can be sufficiently modeled as a simple 
interconversion between two allosteric conformations, despite biophysical evidence for 
multiple inactive and active receptor states. Accordingly we attempted to fit the 
experimentally observed αNb60 and αNb80 values for all ligands using the two-state model 
of receptor activation (Fig. 4a). In this simulation, the equilibrium constant J represents the 
distribution of inactive (R60) and active (R80) receptor states in the absence of ligand. The 
variable β describes the effect that each ligand has on the distribution of receptor states (J), 
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with agonists displaying larger β values (i.e., they stabilize more R80 relative to R60). As 
shown in Figure 4a, the theoretical curve generated by varying β in the two-state model 
(dotted black line) failed to accurately predict the experimentally determined αNb60 and 
αNb80 values for 30% of ligands tested, consisting primarily of partial agonists (dotted red 
oval). A different equilibrium J constant would be required to explain the cooperativity of 
these ligands with the same two-state model. These findings argue that ligands must 
modulate more than these two states to control receptor activation.
Biophysical evidence supports the existence of at least three predominant receptor states; 
therefore we hypothesized that a three-state model (Fig. 4b) may better explain the 
experimentally observed αNb60 and αNb80 values. In this model, the equilibria of R80 (J1) 
and R60 (J2) can be regulated separately by ligands, described by the allosteric factors β1 and 
β2, respectively. We found that the observed cooperativities for 12 ligands (Fig. 4b, class I, 
orange), which encompasses all the full agonists, can be predicted if these ligands primarily 
stabilize the active R80 state while having negligible effects on the inactive R60 state. The 
efficacy of these ligands is thus directly proportionally related to their effect on the R80 
equilibrium (β1), such that highly efficacious ligands have a large β1 (i.e., epinephrine) while 
partial agonists have a lower β1 (i.e., clenbuterol). In contrast, the observed cooperativity of 
other partial agonists (classes II and III) could only be predicted by differentially modulating 
the R80 and R60 equilibria, suggesting these ligands regulate multiple receptor states to 
control receptor activation. For example, even though clenbuterol (CLEN, class I), zinterol 
(ZINT, class II), and procaterol (PROC, class III) are similar partial agonists (Extended Data 
Figure 4a), the mechanism by which they promote receptor activation varies based on their 
ability to differentially stabilize and destabilize the active (R80) and inactive (R60) states, 
respectively (Fig. 4b). Importantly, divergences in receptor activation mechanisms can only 
be uncovered by studying ligand effects at both the Nb60- and Nb80-stabilized β2AR states. 
The inability to accurately predict efficacy (G-protein activation) based on ligand class 
supports the notion that molecular efficacy is a complex process that likely involves many 
more unresolved receptor states.
Our findings significantly reshape current understanding of GPCR activation. For almost 40 
years, studies of these receptors have been guided by the understanding that they can exist in 
two forms, one of high affinity for agonists (active, coupled to G-protein) and one of low 
affinity (inactive, not coupled to G-protein), which are interconverted by the cooperative 
interaction of agonists and guanine nucleotides. We used conformationally sensitive 
nanobodies (Nb60, Nb80) to reveal that Nb60-bound β2AR has affinity ~100-fold lower than 
the previously described low affinity inactive state, which is in fact an “average” of multiple, 
rapidly interconverting inactive and active states. The implication is that the full allosteric 
potential of the β2AR is orders of magnitude greater than formerly appreciated. Moreover, 
binding cooperativity between ligands of varying efficacy and Nb60 and Nb80 could only be 
explained by models featuring multiple (at least three) receptor states, which are 
differentially stabilized and/or destabilized by various agonists. Thus these data demonstrate 
a previously unsuspected heterogeneity in the mechanisms by which different agonists 
stimulate biological responses. In view of the general conservation of GPCR activation 
mechanisms, and a report of an A2A adenosine receptor “Nb60-like” state, these findings 
will likely apply to many GPCRs. Given the primacy of GPCRs as therapeutic targets, these 
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new findings and concepts may also provide a basis for the design of drugs with potentially 
novel therapeutic properties.
 Methods
 β2AR reconstitution in HDL particles
Human β2AR containing an amino-terminal FLAG epitope tag, carboxyl-terminal HIS-tag, 
and a N187E glycosylation mutation was expressed in Sf9 insect cells using the BestBac 
baculovirus system (Expression systems; Davis, CA). Cells were infected at a density of 3 × 
106 cells/mL and harvested 66 hours thereafter. Functional FLAG-β2AR was purified using 
FLAG-M1 antibody and alprenolol affinity chromatography as previously described23. 
FLAG-β2AR was reconstituted into HDL particles (nanodiscs) according to previously 
published methods24. In brief, FLAG-β2AR was incubated with a 50-fold molar excess of 
membrane scaffold protein 1 (MSP1) and 8 mM POPC:POPG (3:2 molar ratio) for 1 hour at 
4°C. Detergent was removed via biobeads overnight at 4°C, and receptor-containing 
nanodiscs were isolated using FLAG-M1 chromatography and size exclusion 
chromatography.
 Nanobody and Gs purification
Nanobodies were generated and purified as previously described6. In brief, Nb60 and Nb80 
clones were originally obtained from one llama (Lama glama) immunized with β2AR 
(truncated at residue 365) reconstituted into liposomes bound to the high affinity agonist 
BI-167107. Nanobody coding sequences were amplified from isolated lymphocyte RNA and 
cloned into phage display vector. Conformationally selective nanobodies were isolated using 
a series of biopanning procedures targeted against native receptor bound to agonist. 
Nanobodies were grown in E. coli WK6 cells and purified from the periplasmic extract using 
nickel-agarose and resource S ion exchange chromatography. Heterotrimeric Gs protein was 
expressed in and purified from Sf9 insect cells using nickel-agarose and ion exchange 
chromatography as described previously25.
 Radioligand binding assays
Competition binding assays (250 µL) contained 60 pM [125I]-CYP, a serial dilution of 
competitor, the indicated concentration of nanobody/Gs, and approximately 0.5 ng of β2AR 
nanodiscs diluted in assay buffer (50 mM Tris-HCl pH 7.4, 12.5 mM MgCl2, 2 mM EDTA, 
0.05% BSA, 1mM L-ascorbic acid). Total binding was determined in the absence of 
competitor; nonspecific binding was determined using 10 µM propranolol. Following a 90 
min incubation at room temperature, binding assays were terminated by rapid filtration onto 
GF/B glass-fiber filters treated with 0.3% PEI and washed with 8 mL of cold binding buffer 
using a harvester (Brandel, Gaitherburg, MD). Bound [125I] was quantified using a Packard 
Cobra Quantum gamma counter (Packard, San Diego, CA) and expressed as specific 
binding. For [3H]-ICI 118,551 binding, 10 ng of β2AR nanodiscs were incubated with 0.3 
nM radioligand and varying concentrations of nanobody and were harvested as described 
above. [I125]-CYP affinity was determined using saturation binding (Extended Data Table 
1). All binding data represent a minimum of three independent experiments with deviation 
represented as standard error.
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 Isothermal Titration Calorimetry (ITC)
ITC experiments were carried out using the MicroCal iTC200 system. β2AR and Nb60, 
purified as described above, were both dialyzed against a buffer consisting of 20 mM 
HEPES pH 7.5, 100 mM NaCl, 0.01% Lauryl Maltose Neopentyl Glycol (MNG), and 
0.001% cholesteryl hemisuccinate (CHS). Protein concentrations were determined by 
measurement of the absorbance at 280 nm, using molar extinction coefficient per cm 
parameters of each protein (ε for β2AR: 66350 cm−1 and Nb60: 21430 cm−1). Nb60 at 100 
µM concentration (40 µL) was loaded into the syringe and titrated into the 200 µL sample 
cell containing β2AR (10 µM) in absence or presence of 200 µM ISO. Titrations were 
performed at 25 °C using an initial injection of 0.5 µL, followed by 2.3 µL injections (1 s 
duration, 300 s spacing, and 5 s filter period). Reference power was set to 10 µcal s−1 and 
stirring speed to 750 r.p.m. Reference titrations were obtained by injecting Nb60 alone or 
Nb60 with agonist (ISO) into sample cells containing buffer alone. To obtain the 
stoichiometry (N) and association constant (KA) of the interaction, the raw data were 
baseline corrected, peak area integrated, and fitted to a one-site non-linear least squares fit 
model using the Origin®7 software program. Binding experiments were performed at least 
twice to calculate standard deviations.
 Enzyme-linked immunosorbent assay (ELISA) for determining Nb KT
The affinity of each nanobody for the unliganded β2AR (KT) was required for TCM data 
analysis. Briefly, 50 ng of carboxypeptidase-treated (to remove His6 tag), biotinylated β2AR 
nanodiscs were immobilized per well of a 96-well SigmaScreen Streptavidin plate in binding 
buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 2 mM EDTA). Following a 3 hr incubation at 
RT, plates were washed four times with binding buffer and incubated with serial dilutions of 
nanobody in binding buffer with 0.1% milk for 2 hr at RT. Plates were quickly washed three 
times with binding buffer and then incubated with polyclonal anti-His HRP-conjugated 
antibody (1:5000, Abcam) in binding buffer with 0.1% milk for 1 hr at RT. Plates were 
quickly washed three times with binding buffer and bound nanobody was detected 
colorimetrically (OD450nm) on a NovoStar plate reader (BMG Labtech) using TMB Ultra 1-
step substrate as described by the manufacturer (Pierce).
 Crystallization of β2AR-carazolol-Nb60 complex
For crystallography trials, we utilized a previously described fusion protein of human β2AR 
with an amino-terminal T4 lysozyme (T4L) fusion and a truncated intracellular loop three26. 
The T4L-β2AR fusion protein was expressed and purified as described above. Purified 
receptor was incubated with 5- and 2-fold molar excess of carazolol and Nb60, respectively. 
The β2AR-carazolol-Nb60 complex was incubated overnight at 4°C and further purified by 
size exclusion chromatography over a Sephadex S200 column in a buffer comprised of 20 
mM HEPES pH 7.5, 100 mM NaCl, 0.01% MNG, and 0.001% CHS. The purified complex 
was concentrated to 37.5 mg/ml and flash frozen in liquid nitrogen for crystallization trials. 
We utilized the in meso crystallization method with a 10:1 (w/w) mix of 7.7 
monoacylglycerol (MAG 7.7) and cholesterol as the host lipid (Avanti Polar Lipids). 
Samples were thawed and reconstituted with the host lipid at a 1:1 ratio with the two-syringe 
mixing method until a clear phase was achieved. The resulting lipidic cubic phase was 
Staus et al. Page 8
Nature. Author manuscript; available in PMC 2017 January 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
dispensed in 35 nL drops onto glass sandwich plates using a GryphonLCP robot (Art 
Robbins Instruments). Crystals grew in a precipitant solution comprised of 100 mM HEPES 
pH 7.5, 20 mM EDTA, and 19–23% PEG300. Although crystals appeared in 2–3 days, the 
best diffraction was obtained from crystals that grew over 30 days. Crystals were harvested 
with mesh loops (Mitegen) and flash frozen in liquid nitrogen.
 Data collection and refinement
X-ray diffraction was collected at the Advanced Photon Source GM/CA beamline 23ID-B. 
As with previous in meso crystallography of GPCRs, crystals suffered considerable radiation 
damage during data collection. Typically, 20–60 degree wedges of data were collected using 
a 20 µm beam. The resulting diffraction data from 10 crystals were processed in 
HKL200027. The structure of the β2AR-carazolol-Nb60 complex was solved by molecular 
replacement using carazolol-bound β2AR with the T4 lysozyme removed (PDB ID: 2RH1) 
and a structure of Nb60 solved to 1.8Å as search models in Phaser28. The model was refined 
iteratively in Phenix29 with manual rebuilding in Coot30 with and without averaging of non-
crystallographic symmetry. The quality of the final model was assessed using MolProbity31 
and refinement statistics are presented in Extended Data Table 2. Figures were prepared 
using PyMOL (Schrödinger). The RMSD analysis for the orthosteric binding pocket was 
performed in PyMOL by measuting residues within 4Å of the ligand carazolol between 
β2AR-Nb60-Cz and 2RH1.
 
19F-NMR of β2AR
19F-fluorine NMR studies were conducted as previously described5. Briefly, full-length 
β2AR with four cysteine mutations (C77V, C327S, C378A, and C406A) was expressed in 
Sf9 cells, extracted using dodecylmaltoside, and purified initially by M1 FLAG affinity 
chromatography. The receptor sample was subsequently labeled with a 
bromotrifluoroacetanilide probe at a 5-fold stoichiometric excess and purified by alprenolol-
sepharose and M1 affinity chromatography. As done for previous 19F-NMR experiments, the 
detergent was gradually exchanged to 0.01% lauryl maltose neopentyl glycol (MNG, 
Anatrace). The final receptor sample was concentrated to 200 µM and a 2.5-fold molar 
excess of carazolol was added prior to acquisition of NMR data. After acquisition of signal 
for the β2AR-carazolol complex, Nb60 was added to a 2.5-fold molar excess, and 19F-NMR 
spectra were obtained for the β2AR-carazolol-Nb60 complex. NMR studies were performed 
at 25°C on a 600 MHz Varian Innova spectrometer equipped with a cryogenic probe capable 
of 19F-NMR (600 MHz). All spectral processing was performed using Mnova 9.0.0 
(Mestrelab Research). Additional information on data processing and line shape simulations 
are described in detail elsewhere5. 19F CPMG relaxation data were recorded by applying 
CPMG frequencies ranging from 500 to 5000 Hz at 600 MHz with a constant time of 2 ms. 
CPMG profiles were fitted to a two state model with Chemex as described elsewhere32. 
The 19F π/2 pulse width was 19 µs.
 Fitting of binding curves with the Ternary Complex Model
The allosteric effect of nanobodies on the binding of receptor ligands is quantified by the 
cooperatvity factor α. Its magnitude is given by a ratio of dissociation constants (i.e., KL/KH 
for Nb80 and KL/KVL for Nb60) determined from the comparison of how each ligand binds 
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to β2AR in the absence of versus the saturating presence of each Nb (Extended Data Figure 
3). However, under conditions in which the nanobody concentration is sub-saturating or the 
radiotracer α is not exactly 1, experimental Kd ratios may underestimate the size of the 
cooperativity factor. To improve measurements of Nb/ligand α values, we fitted the binding 
curves with a mathematical function derived from TCM. This entails solving the following 
nonlinear system of equations that yield the concentration of free species for a binding 
reaction consisting of one receptor (R), one Nb (N) and n ligands (Li) at equilibrium:
where subscripts f and t indicate respectively free and total concentrations and the 
equilibrium binding constants of ligands (K) and nanobody (M) are defined as in 
supplemental (analysis of binding cooperativity). Exact numerical solutions were obtained 
using a globally convergent iterative algorithm33, which was coded as add-in function for 
MS-Excel34. The built-in optimizer “Solver” was used to minimize the sum of squares 
difference between predicted and experimental data (choosing the Newton search option and 
setting convergence threshold at 10−12). Sets of 3 curves representing bound radiotracer as a 
function of increasing concentrations of unlabeled ligand, obtained in the absence and 
presence of Nb80 or Nb60, were fitted simultaneously. Known parameters are the M of each 
Nb (Extended Data Figure 6), the K and α value of [125I]-CYP (Extended Data Figure 1). 
Unknown fitted parameters are: non-specific tracer binding, receptor concentration and K 
value of the competing ligand (both shared across the 3 curves), and the individual αNb80, 
αNb60 values for each ligand/Nb pair. For data measured in the presence of Gs (the M value 
of which was not available), all ligands curves were fitted globally and constrained to share a 
common best-fitting M. This fitted value was close to that experimentally measured for 
Nb80.
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 Extended Data
Extended Data Figure 1. Characterization of Nb60 interaction with β2AR
Competition equilibrium binding studies using [125I]-cyanopindolol (CYP), the cold 
competitor agonist isoproterenol (ISO), β2AR in HDL particles, and the indicated 
concentration of (a) Nb80, (b) Gs, or (c) Nb60. Dotted vertical line represents logIC50 in 
absence of modulator, and the change in ligand affinity is depicted with colored arrows. (d)
19F-NMR CPMG relaxation dispersion experiment with β2AR-Nb60-Carazolol (Cz). Kex – 
Exchange Rate. (e) Competition equilibrium binding studies using [125I]-CYP, the non-
labeled competitor agonist ISO, β2AR in HDL-particles, and 1 µM Nb60 WT or T102A/
F103A. (f) ELISA depicting capture of β2AR by Nb60 or the T102A/F103A variant. Inset: 
Coomassie stain of nanobody input. Radioligand binding and ELISA experiments were 
performed at least three times with deviation shown as standard error.
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Extended Data Figure 2. Characterization of β2AR-Nb60-carazolol crystals
(a) Monodispersity of T4L-β2AR-Nb60-carazolol (β2AR-Nb60-Cz) complex as assessed by 
size exclusion chromatography. Inset: Coomassie stain illustrating presence of β2AR and 
Nb60 in fractions combined for crystallography. (b) Representative picture of β2AR-Nb60-
Cz lipidic cubic phase (LCP) crystals. (c) Insertion of F103 (green) from Nb60 CDR3 
(purple) into hydrophobic β2AR pocket, nitrogen and oxygen shown as blue and red shaded 
surfaces, respectively. (d) Example of β2AR-Nb60-Cz crystal lattice. (e) Electron density 
2FO-FC map (Sigma: 1) of carazolol binding pocket (top panels) Nb60 CDR3 binding 
pocket (bottom panels) within β2AR.
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Extended Data Figure 3. Differential effects of Nb60 and Nb80 on the affinity of 12 different 
β2AR ligands
Competition equilibrium binding studies using [125I]-cyanopindolol (CYP), the indicated 
non-labeled competitor, β2AR in HDL-particles, and 1 µM of Nb60 or Nb80. Data represent 
at least three independent experiments with deviation depicted as standard error.
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Extended Data Figure 4. Agonist induced G-protein activation in cellulo correlates with the 
magnitude of affinity change mediated by Nb80 in vitro
(a) Table representing cell signaling and ligand affinity data. Ligand-dependent G-protein 
activation was quantified by measuring cAMP levels (GloSensor, Promega) from HEK293 
cells over-expressing β2AR. Ligand affinity was measured in membranes prepared from the 
same cells as above using competition binding assays with [125I]-CYP. Ligand efficacy (log 
Tau) was calculated as previously described36. See methods and supplemental material for 
cooperativity (α) determination. Correlation plot of logTau and αNb80 (b) or αNb60 (c). All 
data represent at least three independent experiments with deviation shown as standard error.
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Extended Data Figure 5. Positive correlation between allosteric properties of Nb80 and Gs
(a) Equilibrium binding studies using HDL-β2AR, [125I]-cyanopindolol, the indicated 
unlabeled competitor, and 100 nM purified heterotrimeric Gs-protein. (b) Correlation plot of 
cooperativity values (α) for Nb80 and Gs. (c) Sequence alignment of Nb60 and NbA11. 
Radioligand competition binding studies with Nb80, Nb60 or NbA11, [125I]-cyanopindolol, 
the unlabeled competitor isoproterenol or clenbuterol, and HDL-β2AR. All data represent at 
least three independent experiments with deviation shown as standard error.
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Extended Data Figure 6. Affinity determination for Nb60 and Nb80 for unliganded β2AR
ELISA assay detecting capture of increasing concentrations of Nb60 or Nb80 by 
immobilized HDL-β2AR in the absence of ligand. All data represent at least three 
independent experiments with deviation shown as standard error.
Extended Data Figure 7. Theoretical framework illustrating the two views of allostery
(a) Nested reaction schemes at equilibrium indicating the correspondence (arrowed light-
blue shades) between binding site cooperativity (TCM in outer box) and changes of 
allosteric conformations (inner cubes). Arrows stand for reversible equilibrium interactions. 
(b) Change of the macroscopic dissociation constant (1/K) of a ligand L (shifting the 
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equilibrium towards r1) induced by increasing the concentrations of nine different N-ligands 
with diverse allosteric effects (γ1, γ2) on receptor states. Simulations were made using a 3-
state model based on the parameter values listed on the right side of the plot (curves on the 
left side are color coded in red/blue tones according to right-side boxes). The change in K 
(i.e. log difference between presence and absence of N) is calculated from eq. 1 in SI 
(Analysis of nanobody allostery).
Extended Data Figure 8. Comparison of experimental and theoretical cooperativities predicted 
according to a 2-state (a–d) or 3-state (e, f) allosteric models
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(See also SI, “Analysis of nanobody allostery.”) (a–d d) Theoretical log α values were 
computed according to a 2-state model for a series of hypothetical ligands (L) (log β1 range: 
−4/8) and a positive (PAN, log γ1 >>0) or negative (NAN, log γ1 << 0) nanobody. (a) 
Observed data overlaid on values simulated at J1 = 8.9 × 10−4 in histogram form (with 
experimental bars drawn on the closest theoretical log β1 bin value), or superimposed (b) on 
the log αNAN vs. log αPAN relationships predicted for different J1 values. The same data are 
replotted as separate graphs for lower J1 (c) and larger J1 (d) values, to show the sigmoid 
relationships existing between macroscopic log α’s and log β1. (e, f) Simulations made 
according to the 3-state allosteric model: (e) predicted (lines) and observed (circles) log α 
values plotted as functions of log (β1/β2). Three groups of ligands (I to III, defined by the 
table of a0 and m parameters) produce increasingly stronger reductions of r2 equilibrium. (f) 
Same data plotted as log αNb60 vs. log αNb80 relationships (see fig. 4, main paper). All α 
values derived from at least three independent radioligand binding experiments with 
deviation depicted as standard error.
Extended Data Table 1
Effect of Nb60 and Nb80 on [125I]-Cyanopindolol affinity.
[125l]-Cyanopindolol Affinity Kd Ratio
Kd (pM) SEM Control/Nb SEM
Control 737.3 92.9 ---- ----
Nb80 315.6 62.4 2.5 0.35
Nb60 663.0 17.7 1.1 0.12
Extended Data Table 2
Data collection and refinement statistics (molecular replacement).
β2AR-Carazolol-Nb60a
Data collectionb
Space group P212121
Cell dimensions
  a, b, c (Å) 43.9, 164.5, 218.8
  α, β, γ (°) 90.0, 90.0, 90.0
Resolution (Å) 32.9–3.2 (3.30–3.20)
Rmerge (%) 17.5 (89.6)
<I/σI> 5.3 (1.5)
CC1/2 (%) 98.6 (82.4)
Completeness (%) 98.6 (95.5)
Redundancy 5.5 (4.6)
Refinement
Resolution (Å) 32.9–3.2 (3.30–3.20)
Number of reflections 26,778
Rwork/Rfree (%) 24.7/29.0 (38.3/43.9)
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β2AR-Carazolol-Nb60a
Number of atoms
  Protein 7,703
  Ligand (Carazolol) 44
  Solvent (lipid, water, other) 56
B-factors (Å2)
  Protein 129.81
  Ligand (Carazolol) 116.36
  Solvent (lipid, water, other) 157.51
R.M.S. deviation from ideality
  Bond lengths (Å) 0.003
  Bond angles (°) 0.429
Ramachandran statisticsc (%)
  Favored 96.8
  Allowed 3.2
  Outliers 0
a
Diffraction data from 10 crystals were merged into a complete data set.
b
Highest resolution shell statistics are shown in parentheses.
cAs calculated by Molprobity.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Allosteric nanobodies have opposing effects on agonist affinity for the β2AR
(a) Schematic of the ternary complex model (TCM). Ligand (L) affinity to receptor (R) 
increases in the presence of transducer (T), this allosteric linkage is denoted by dashed line 
with arrows. (b) Compared to the absence of modulator, Nb60 decreases ISO affinity 
(negative cooperativity) and Nb80/Gs increases affinity (positive cooperativity) as assessed 
by radioligand competition assays using β2AR HDL-particles. (c) The effects of Nb60 and 
Nb80/Gs on ISO affinity are saturable functions of their concentration. The affinity of Nb60 
for unliganded β2AR (d), represented by a tight isotherm sigmoidal binding curve35, is 
reduced in the presence of ISO (e) as determined by isothermal titration calorimetry. (f) 
Nb60 dose dependently increases and Nb80 decreases the binding of the radiolabeled 
antagonist [3H]-ICI-118,551 to the β2AR. All radioligand binding studies represent a 
minimum of three independent experiments with deviation shown as standard error.
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Figure 2. Nb60 stabilizes the S2 inactive state by coordinating the β2AR ionic lock
Cartoon depicting a side (a) or cytoplasmic (b) view of the β2AR transmembranes (TM). 
Conversion from the two inactive states (S1 and S2) to the active S4 state requires both 
agonist and transducer (i.e. G-protein) binding and is represented by a 14Å outward 
movement of TM6. (c) 19F-NMR spectroscopy of the β2AR with the antagonist carazolol 
(Cz) +/− Nb60. (d) The 3.2Å structure of the β2AR bound to carazolol and Nb60 (β2AR-Cz-
Nb60). (e) Coordination of β2AR ionic lock (R131 and E238) by Nb60 CDR3 residues T102 
and Y106. For comparison, a disengaged and fully formed ionic lock are shown by the 
β2AR-Cz (PDB ID: 2RH1) and β1AR-Cz (PDB ID: 2YCZ), respectively. Hydrogen bonds 
shown as black dotted lines. (f) Overlay of β2AR-Cz and β2AR-Cz-Nb60 structures.
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Figure 3. Nb60 and Nb80 have varying effects on the affinity of different β2AR ligands
(a) Schematic depicting the use of equilibrium radioligand binding studies to quantify the 
cooperativity (α) between Nb60 or Nb80 binding and ligand affinity (see methods and 
supplemental information). (b) Cooperativity values for Nb60 (αNb60) and Nb80 (αNb80) 
for β2AR ligands with varying efficacies. Ligands are ordered by magnitude of αNb80. (c) 
Correlation plot of αNb60 and αNb80; regression shown as solid red line with 95% 
confidence interval (dotted red line). All α values derived from at least three independent 
radioligand binding experiments with deviation depicted as standard error.
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Figure 4. β2AR agonists differentially stabilize receptor states to regulate receptor activation
Illustration of a two- (a) or three-state (b) model of receptor activation describing the effect 
of β2AR ligands on receptor conformations stabilized by Nb60 (R60) or Nb80 (R80). The 
equilibrium (J) between receptor states can be influenced by ligand binding through the 
allosteric factor β. The theoretical cooperativity (α) between nanobody and ligand binding 
derived from the 2-state model (dashed black line) fails to predict the observed α values for 
a subset of ligands (dashed red oval). However, the observed cooperativity values can be 
accurately predicted using an allosteric model in which ligands can differentially modulate 
three independent receptor states (3-state). Certain ligands (orange) primarily stabilize the 
active R80 state, whereas others (purple, green) can stabilize R80 but simultaneously 
destabilize the inactive R60 state. All α values derived from at least three independent 
radioligand binding experiments with deviation depicted as standard error.
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